Frankfurt - Delayed Quote EUR

Harvard Bioscience, Inc. (HBI.F)

Compare
1.8300
-0.0500
(-2.66%)
At close: January 17 at 9:04:14 AM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. James W. Green President, CEO & Chairman 601.37k -- 1958
Ms. Jennifer Cote CPA, CGMA CFO & Treasurer 350.71k -- 1972
Mr. John J. Fry J.D. Chief Legal Counsel & Corporation Secretary -- -- 1961
Mr. Ryan Wallace Senior Vice President of Global Sales -- -- --
Ms. Lori Packer Vice President of Global People Operations -- -- --
Kathryn Flynn Corporate Controller -- -- --
David Sirois Director of Corporate Accounting & SEC Reporting -- -- --

Harvard Bioscience, Inc.

84 October Hill Road
Suite 10
Holliston, MA 01746
United States
508 893 8999 https://www.harvardbioscience.com
Sector: 
Healthcare
Full Time Employees: 
391

Description

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Corporate Governance

Harvard Bioscience, Inc.’s ISS Governance QualityScore as of January 1, 2025 is 6. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 7; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 5, 2025 at 1:30 PM UTC - March 10, 2025 at 1:30 PM UTC

Harvard Bioscience, Inc. Earnings Date

Recent Events

Waiting for permission
Allow microphone access to enable voice search

Try again.